Financial Performance - Total operating revenue for 2024 was CNY 578,276.69 million, a decrease of 5.34% compared to the previous year[4] - Operating profit fell to CNY 7,513.99 million, down 84.64% year-on-year[4] - Net profit attributable to shareholders decreased by 89.92% to CNY 5,105.20 million[4] - Basic earnings per share decreased by 88.24% to CNY 0.02[4] - The weighted average return on net assets dropped to 0.59%, down 5.38 percentage points from the previous year[4] - Non-recurring gains and losses amounted to CNY 2,697.28 million, down 79.42% year-on-year, primarily due to reduced government subsidies[6] Asset and Equity Status - The company's total assets at the end of the reporting period were CNY 1,115,720.81 million, a decline of 5.73% from the beginning of the period[6] - Shareholders' equity attributable to the company was CNY 867,347.67 million, a slight decrease of 0.42%[6] Impairment and Provisions - The provision for asset impairment increased by 83.34% compared to the previous year, negatively impacting profits[6] Profit Distribution - The company has not yet discussed the profit distribution plan for 2024[8]
红日药业(300026) - 2024 Q4 - 年度业绩